This conference will examine the potential effect on the pharmaceutical industry of negoitations currently under way at the World Health Organisation which could see a fundamental change to the global IP rules which currently underpin R&D. The conference will survey the political and economic context behind the WHO negotiations, and offer perspectives into the likely impact on innovation and health of the reforms under discussion. It will also provide a valuable forum for discussion of these complex issues.